A trial fibrillation (AF) substantially increases the risk of major adverse clinical outcomes, such as stroke 1,2 and death. 3 Yet, AF can also cause frequent symptoms, affect patient's functional status, and impair their quality of life. 4 Although prior studies have reported the range of AF-related symptoms in patient populations, these studies were generally from highly selected patients and referral-based practices and may not reflect results in community practice or results with contemporary AF management.. [5] [6] [7] [8] Additionally, although disease-specific symptom and quality of life assessment tools have been developed for AF, these tools have not been well assessed in large communitybased populations. For example, the European Heart Rhythm Association (EHRA) has proposed a scoring system for AF-related symptoms (1=asymptomatic, 2=mild, 3=severe, 4=disabling), 9,10 but it remains unstudied in a large clinical cohort. Like the New York Heart Association classification Background-Instruments to assess symptom burden and quality of life among patients with atrial fibrillation (AF) have not been well evaluated in community practice or associated with patient outcomes. Methods and Results-Using data from 10 087 AF patients in the Outcomes Registry for Better Informed Treatment of AF (ORBIT-AF), symptom severity was evaluated using the European Heart Rhythm Association (EHRA) classification system, and quality of life was assessed using the Atrial Fibrillation Effect on Quality-of-Life (AFEQT) questionnaire. The association between AF-related symptoms, quality of life, and outcomes was assessed using Cox regression. The majority of AF patients (61.8%) were symptomatic (EHRA >2) and 16.5% had severe or disabling symptoms (EHRA 3-4). EHRA symptom class was well correlated with the AFEQT score (Spearman correlation coefficient −0.39). Over 1.8 years of follow-up, AF symptoms were associated with a higher risk of hospitalization (adjusted hazard ratio for EHRA ≥2 versus EHRA 1 1.23, 95% confidence interval, 1.15-1.31) and a borderline higher risk of major bleeding. Lower quality of life was associated with a higher risk of hospitalization (adjusted hazard ratio for lowest quartile of AFEQT versus highest 1.49, 95% confidence interval, 1.2-1.84), but not other major adverse events, including death. Conclusions-In a community-based study, most patients with AF were symptomatic and had impaired quality of life.
for heart failure, the EHRA reflects physicians' perspectives of patients' health status (symptoms, function, and quality of life) and may offer a simple and valuable tool for guiding treatment decisions and conducting research. Similarly, the Atrial Fibrillation Effect on Quality-of-Life (AFEQT) questionnaire 11 was recently developed as a disease-specific tool for assessing quality of life and health status from patients' perspectives, but has yet to be evaluated in a large community-based patient cohort. Finally, the association between AF-related symptoms or quality of life from these assessment tools with clinical outcomes, including death, hospitalization, stroke, myocardial infarction, or major bleeding events, has not been previously evaluated.
Using the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF), a large, contemporary, prospective, community-based outpatient cohort, we evaluated the type and frequency of symptoms in patients with AF. In addition, we measured the degree to which symptom severity (using the EHRA classification system) was correlated with quality of life (assessed by the AFEQT questionnaire) and the association between symptoms or quality of life with clinical outcomes, including death, hospitalization, stroke, and major bleeding.
Methods

ORBIT-AF Registry
The ORBIT-AF is an ongoing national, observational, communitybased, registry of outpatients with AF. The ORBIT-AF study has been described previously. 12 The primary data set for this analysis included baseline data for 10 132 patients >18 years of age with electrocardiographically documented AF collected between June 2010 and August
Study Population
We enrolled 10 132 patients >18 years of age with electrocardiographically documented AF. For the current analysis, 45 patients without documented EHRA status were excluded, leaving 10 087 patients in the study cohort. Patient quality of life data were derived from a subsample of 2006 (19.8%) subjects administered a patient-reported outcome questionnaire at the baseline visit. Of the sites in the main cohort, 58% participated in the quality of life survey. All patients enrolled in the main cohort at these sites were approached to complete the questionnaire on a voluntary basis until the quality of life subsample enrollment goal was met. Of the patients with documented EHRA status, 2006 patients were administered the patient-reported outcome questionnaire. All subjects provided written, informed consent. Institutional review boards of the Duke Clinical Research Institute and the participating enrollment sites approved the study.
Physician-Assessed Symptom Burden, Patient-Reported Symptoms and Quality of Life, and Outcomes
At baseline, we assessed physician-assessed AF symptom burden (EHRA score) and patient-reported AF symptoms and quality of life (AFEQT score). Individual patient-reported symptoms were assessed, including palpitations, syncope or fainting, dyspnea on exertion, exercise intolerance, lightheadedness or dizziness, dyspnea at rest, fatigue, and chest tightness or discomfort. In addition, physicianassessed AF symptom severity and burden was assessed by treating physicians using the EHRA symptom classification defined as asymptomatic (EHRA 1), mild symptoms (EHRA 2), severe symptoms (EHRA 3), and disabling symptoms (EHRA 4). 9, 10 Treating physicians were blinded to the patient AFEQT responses when providing EHRA scores.
Quality of life data were derived from the patient-reported outcome questionnaires administered to a subsample of ≈20% of patients from the overall ORBIT-AF registry population. All patients at sites agreeing to participate in the questionnaire substudy were approached until the enrollment goals were met. The baseline characteristics were similar between the overall cohort and the subsample cohort ( Table I in the Data Supplement) . AF-related quality of life was measured in this group using the previously validated AFEQT questionnaire (St Jude Medical, St Paul, MN). The AFEQT is a 20item questionnaire assessing 3 domains of AF-related quality of life, including activity, symptoms, and treatment concerns. 11, 13 An overall summary score can be calculated from these domains and was used for the primary analyses in this study.
Follow-up data collection occurred at 6-month intervals for a minimum of 2 years. The primary outcomes for this analysis were all-cause death, first hospitalization, first stroke or transient ischemic attack, first myocardial infarction, and first major bleeding event using standard definitions. 12 Primary outcome events were verified by single-source document submission (eg, hospital discharge report) and central review at the data coordinating center. Outcomes within the first 2 years of baseline enrollment were analyzed.
Statistical Analysis
All analyses were performed using SAS statistical software (version 9.3, SAS Institute, Cary, NC). We compared the baseline
WHAT IS KNOWN
• Atrial fibrillation causes symptoms, such as palpitations and dyspnea with exertion and may decrease patient quality of life.
WHAT THE STUDY ADDS
• characteristics for patients in the ORBIT-AF study population overall and according to the EHRA symptom classification as asymptomatic (EHRA 1) or symptomatic (EHRA ≥2) using the χ 2 test for categorical variables and the Wilcoxon rank-sum test for continuous/ ordinal variables. We also compared the baseline characteristics for the subset of patients in the ORBIT-AF study population who completed the AFEQT patient-reported outcome questionnaire overall and according to quartiles of the AFEQT score using the χ 2 test for categorical variables and the Kruskal-Wallis test for continuous/ ordinal variables. AF symptom prevalence was calculated using frequencies and percentages overall and by each EHRA symptom class, which were then compared using the χ 2 test for categorical variables. AFEQT overall scores were calculated and compared across EHRA symptom classes using the nonparametric Kruskal-Wallis test for continuous variables. The Spearman rank correlation coefficient was calculated between overall AFEQT score and EHRA class. AFEQT overall scores were calculated for each AF symptom (present/absent) and compared using the nonparametric Wilcoxon rank-sum test for continuous variables.
Using multiply imputed data, Cox frailty regression modeling (which takes into account clustering of patient outcomes within a site by adding a random effect for site) was used to examine the association between EHRA classes or AFEQT scores at baseline and clinical outcomes during follow-up. Previously developed models for each outcome were used for adjustment. 14 Briefly, a multiply imputed data set was used for model construction. Using the first imputed data set, all continuous variables were evaluated for nonlinearity with the outcome while adjusting for 55 candidate variables. Those which did not meet the linear relationship criteria (P value <0.05) were accounted for using linear splines. Backward selection with stay criteria of P value <0.05 was then performed on the first imputed data set to construct the Cox frailty regression model for each outcome using the variables from the list of 55 candidate variables. Rates of missingness were <2% for all candidate variables in the model, with the following exceptions: level of education (4%), eGFR (8%), left ventricular ejection fraction (11%), hematocrit (11%), and left atrial diameter (14%). All available follow-up data were used in the model construction process. Imputed values were obtained by the Markov chain Monte Carlo method or regression methods. 15 The results from each model were then combined to produce statistically valid inferences when imputed data sets were used. Adjusted associations for outcomes were displayed as hazard ratios, 95% confidence intervals, and P values. For the evaluation of the association between AF symptoms and outcomes, the risk of each outcome for those with an EHRA score of 1 was compared with the risk of each outcome for those with an EHRA score of ≥2. For the evaluation of the association between quality of life and outcomes, the risk of each outcome for those in the highest quartile of AFEQT was compared with those in each of the other quartiles. A hazard ratio and P value were generated for each of these comparisons and a global P value was generated for the highest quartile compared with all of the other quartiles.
Kaplan-Meier estimates were used to calculate the mortality curves by EHRA score and AFEQT quartiles. We estimated the cumulative incidence rate by EHRA score and AFEQT quartiles for the all-cause hospitalization curves. This method accounts for the competing risk of mortality, which makes it impossible for a patient to experience a subsequent hospitalization.
All statistical analyses for this study were performed using SAS software (version 9.3, Cary, NC). All P values were 2-sided.
Results
Baseline Characteristics Stratified by Symptom Status
Among 10 087 adults who had AF between June 2010 and August 2011, 6235 (61.8%) were symptomatic at baseline as defined by the physicians-assessed EHRA classification system and 3852 (38.2%) were asymptomatic (Table 1) .
Patients with AF symptoms were less likely to be male (53.6% versus 64.3%, P<0.0001). They were also more likely to have heart failure, chronic obstructive pulmonary disease, frailty, 16 and obstructive sleep apnea. They were more likely to have a lower (but normal range) left ventricular ejection fraction. Patients with symptoms were more likely to have paroxysmal AF (53.8% versus 45.3%, P<0.001). Symptomatic patients were treated less with angiotensin-converting enzyme inhibitors, calcium channel blockers, statins, and warfarin, but more with antiarrhythmic medications. Other clinical differences were small in absolute terms (<2.5%) yet were statistically significant because of the large sample size in the study.
Patient-Reported Symptoms and EHRA Symptom Severity Class
The most common patient-reported symptoms were palpitations (32.7%), dyspnea with exertion (27.6%), fatigue (26.4%), and lightheadedness or dizziness (20.6%; Table 2 ). Less common symptoms included dyspnea at rest (10.3%), exercise intolerance (10%), chest tightness or discomfort (9.4%), and syncope (4.5%).
Using the EHRA classification system, 61.8% of patients had at least mild symptoms and 16.5% had severe or disabling symptoms. Among those identified by physicians as asymptomatic using the EHRA score, the vast majority reported no individual symptoms, but 11% reported at least one symptom, with palpitations being most common (6%). Among those assessed by physicians as having mild to disabling symptoms (EHRA 2-4), the most common patientreported symptoms were palpitations (49.1%), dyspnea with exertion (43.1%), fatigue (41.1%), and lightheadedness or dizziness (32.0%). The prevalence of these symptoms increased ≤2-fold as EHRA symptom severity increased from mild (EHRA 2) to disabling (EHRA 4). Less common symptoms among those with EHRA mild to disabling symptoms included dyspnea at rest (16.3%), exercise intolerance (15.6%), chest tightness or discomfort (14.9%), and syncope (6.9%). The prevalence of these symptoms increased 4-to 5-fold as EHRA symptom severity increased from mild (EHRA 2) to disabling (EHRA 4).
Baseline Characteristics in the Quality of Life Substudy
In the quality of life substudy, 2007 adults completed the patient-reported outcome AFEQT questionnaire and 2006 patients had adequate data for subsequent analysis. There were no substantial differences between the patients in the overall cohort and the patients in the quality of life substudy population (data not shown). Patients in the highest quartile of quality of life had AFEQT scores of 93.5 to 100, whereas those in the lowest quartile of quality of life had AFEQT scores of 0 to 65.7 ( Table II in the Data Supplement) .
Patients in the lowest quartile of quality of life compared with those in the highest quartile were younger (73 versus 78 years, P<0.001) and more likely to be female (50.5% versus 36.1%, P<0.0001). Those with worse quality of life were more likely to have a history of peripheral vascular disease, congestive heart failure, chronic obstructive pulmonary disease, and obstructive sleep apnea. They were also more likely to have new onset AF and less likely to have paroxysmal or long-standing persistent AF. They had higher body weights and were more likely to be taking aldosterone antagonists and diuretics. Other clinical differences were small in absolute terms (<2.5%), yet were statistically significant because of the large sample size in the study.
Atrial Fibrillation Effect on Quality-of-Life Questionnaire Score
As with the overall cohort, the most common symptoms in the subgroup of patients who completed the AFEQT survey were palpitations (33.0%), dyspnea with exertion (32.6%), fatigue (32.0%), and lightheadedness or dizziness (27.3%; Table III in the Data Supplement). The prevalence of every symptom was highest among those in the lowest quartile of quality of life and decreased with increasing quality of life. All of the symptoms assessed were associated with a statistically significant decrease in quality of life (P<0.001) with a decrement of AFEQT score ranging from 9 to 17 ( Figure 1 ). Dyspnea at rest, exercise intolerance, and chest discomfort or tightness were associated with the largest decreases in quality of life as measured by the AFEQT.
Correlation of EHRA Classification and Quality of Life
Patients assessed by physicians to be asymptomatic (EHRA=1) had the highest quality of life as measured by the AFEQT, and the AFEQT score decreased with increasing
Table 2. Atrial Fibrillation-Associated Symptoms in 10 087 Adults With Atrial Fibrillation in the ORBIT-AF Registry Enrolled Between June 2010 and August 2011 Overall and Stratified by European Heart Rhythm Association (EHRA) Symptom Severity Classification
Atrial Fibrillation Symptom
Overall (N=10 087) EHRA symptom severity class with a Spearman's correlation coefficient of −0.39 ( Figure 2 ). Those assessed by physicians as asymptomatic (EHRA=1) had a median AFEQT score of 90 (interquartile range [IQR] 79-97), those with mild symptoms (EHRA=2) had a median score of 81 (IQR 67-91), those with severe symptoms (EHRA=3) had a median score of 63 (IQR 48-82), and those with disabling symptoms (EHRA=4) had a median score of 61 (IQR 41-78).
AF-Related Symptoms and Quality of Life and Associations With Outcomes
Over a median of 1.8 years (IQR 1.4-2.1 years) of follow-up in 9600 adults with follow-up data, patients with AF-related symptoms at baseline (EHRA≥2) had a higher risk of hospitalization (adjusted hazard ratio 1.23, 95% confidence interval 1.15-1.31, P=<0.001, Table 3 , Figure 3) ) and a borderline higher risk of major bleeding (adjusted hazard ratio 1.21, 95% confidence interval 1.02-1.45, P=0.03). In contrast, AFrelated symptoms at baseline were not associated with significant differences in the risk of death (Figure 4) , stroke, or myocardial infarction. Among 1925 adults with follow-up data, patients in the lowest quartile of quality of life at baseline (AFEQT ≤65.7) had a higher risk of hospitalization compared with those in the highest quartile (AFEQT >93.1; adjusted hazard ratio 1.49, 95% confidence interval 1.2-1.84, P≤0.001, Table 4 , Figure I in the Data Supplement). This finding was consistent for the comparison of the second and third quartiles compared with highest quartile of quality of life, and the global P value for all of the other quartiles compared with the highest quartile was 0.001 (Table 4 ). In addition, this finding was consistent when AFEQT was modeled as a continuous variable (Table IV in the Data Supplement). In contrast, quality of life at baseline was not associated with significant differences in the risk of death ( Figure II in the Data Supplement) or major bleeding. The number of events for stroke/transient ischemic attack and myocardial infarction did not differ substantially between quartiles of quality of life, but they were not adequate to perform our regression models for risk assessment.
Discussion
In a large, diverse, community-based cohort of adults with AF, we found that most patients (61.8%) were symptomatic as measured by the EHRA classification system. The most common symptoms were palpitations, dyspnea with exertion, fatigue, and lightheadedness or dizziness. Symptom severity measured by physicians using the EHRA classification was correlated with decreasing patient-reported quality of life as measured by the AFEQT questionnaire. AF symptoms were associated with a higher risk of hospitalization and a borderline higher risk of major bleeding, and decreased quality of life was associated with a higher risk of hospitalization, but there were no differences in the risk of death or other major adverse events.
This study is novel in its use of the EHRA AF symptom classification system in a large, community-based cohort and its demonstration of a correlation between physician-assessed AF symptom status and patient-reported quality of life. Although most patients in our cohort were assessed by physicians as symptomatic (EHRA 2-4), 38.2% were reported to be asymptomatic (EHRA 1). Interestingly, 11% of those assessed as asymptomatic by physicians (EHRA 1) reported experiencing individual symptoms, with palpitations being the most common, suggesting that physicians may underestimate patient symptoms when they are mild. Regardless, this frequency of asymptomatic patients is substantially higher than has previously been reported, likely because of selection biases in prior studies. [5] [6] [7] [8] Prior studies reporting higher symptom burden included selected patients from referral-based practices, and therefore our community-based population likely more accurately represents the prevalence of symptoms in outpatients with AF.
The AFEQT questionnaire 11 has been validated as a disease-specific tool for assessing patient quality of life in AF, but it has not previously been used in a large community-based cohort. All of the symptoms assessed in our study were associated with statistically significant decreases in quality of life, but dyspnea at rest, exercise intolerance, and chest discomfort or tightness were associated with the largest decreases. This is consistent with our finding that these symptoms, although relatively rare overall, were common among those who reported severe or disabling symptoms (EHRA 3-4) in our cohort and deserve special attention by treating clinicians.
We demonstrated an inverse correlation between the EHRA AF symptom severity classification system and quality of life as measured by the AFEQT in our population. This consistency across test instruments supports their clinical use for assessment of AF symptom burden and quality of life. We also demonstrated that those with mild symptoms (EHRA 2) had an AFEQT score of <90 and those with severe or disabling symptoms (EHRA 3-4) had an AFEQT score of <64. These AFEQT thresholds may serve as clinically significant quality of life categories for future clinical trials or observational studies. *Variables included in the adjusted models (baseline covariates): Death adjusted for level of education, rhythm control, cognitive impairment/dementia, hyperlipidemia, linear spline eGFR ≤80, linear spline eGFR >80, LAD bypass graft type, cancer, diastolic blood pressure, intraventricular conduction delay, frailty, height, heart rate, hematocrit, diabetes mellitus, smoking, linear spline systolic blood pressure ≤120, COPD, BMI, sex, CHF, age, functional status. Stroke adjusted for peripheral vascular disease, race, rhythm control, AF type, AV node/His bundle ablation, female, hypertension, age, history of stroke/TIA. MI adjusted for diabetes mellitus, eGFR, peripheral vascular disease, history of CAD, LVEF. Hospitalization for linear spline age ≤70, linear spline age >70, BMI, weight, osteoporosis, height, PCI, cancer, OSA, anemia, frailty, insurance status, history of CAD, site specialty, prior antiarrhythmic drug use, peripheral vascular disease, functional status, linear spline heart rate >68, diabetes mellitus, hematocrit, linear spline eGFR ≤80, COPD, diastolic blood pressure truncated above at 70, EHRA score, CHF. Major bleeding adjusted for COPD, OSA, LAD type, cancer, functional status, level of education, intraventricular conduction delay, rhythm control, smoking status, significant valvular disease, eGFR, insurance status, history of gastrointestinal bleed, anemia, hematocrit. July 2015 Finally, our study demonstrated an association between physician-assessed AF symptom burden (EHRA) and patient-reported decrease in quality of life and a higher risk of hospitalization. We did not show any differences in the risk of death or other major adverse events, except for a borderline association between AF symptoms assessed by EHRA class and hospitalization. This finding is noteworthy because the patients with the highest burden of symptoms and the lowest quality of life were substantially younger and healthier than less symptomatic patients and those with higher self-reported quality of life. These patients did not have an increased risk of death, stroke, myocardial infarction, or major bleeding, suggesting that their hospitalizations were likely related to their symptoms and lower quality of life and not major adverse events. Interventions targeted at improvement in symptoms and quality of life in these patients, including more aggressive outpatient follow-up or rhythm control therapies may be important for minimizing resource utilization in this population.
Our study has important limitations. Although our large, community-based cohort is broadly representative of patients with AF in the United States, we evaluated patients who are undergoing treatment for AF, and the results may not be generalizable to a disadvantaged or untreated population. In addition, the population of patients who chose to participate in the quality of life substudy may not be fully generalizable to a general population with AF. Finally, despite controlling for a large number of covariates, we cannot exclude residual or unmeasured confounding in our analyses, evaluating the association between AF symptoms or quality of life and outcomes.
Conclusions
In summary, in a large nationally representative communitybased cohort of individuals with AF, most patients were reported by physicians to be symptomatic (61.8%) and a substantial minority (16.6%) had severe or disabling symptoms (EHRA 3-4). The most common patient-reported symptoms reported in our cohort were palpitations, dyspnea with exertion, fatigue, and lightheadedness or dizziness. We demonstrated that physician-assessed AF symptom burden using the European Heart Rhythm Association (EHRA) classification system correlated with decreased patient-reported quality of life as measured by the AFEQT questionnaire, supporting the clinical use of both instruments. Finally, our study demonstrated an association between AF-related symptoms or decreased quality of life and a higher risk of hospitalization, although not mortality, thus identifying an important population of patients who may require aggressive interventions to minimize symptoms and lower resource utilization.
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†There were not enough events for the unadjusted and adjusted models for stroke/TIA and MI.
